Science

Aug 23, 2025, 09:00

GLP-1 Receptor Agonists and Cancer Risk in Adults With Obesity – UF Health Cancer Center

UF Health Cancer Center shared a post on LinkedIn:

“A new study by University of Florida researchers and collaborators has found that a popular class of weight loss drugs is associated with lower cancer risk.

Published today in JAMA Oncology, the large observational study used real-world data from OneFlorida+, a powerful multi-state resource of anonymous health records created by the University of Florida, Clinical & Translational Science Institute (CTSI) and the UF Health Cancer Center. Researchers compared cancer risk in 43,317 adults with obesity or who were overweight who were using the weight loss drugs with 43,315 who were not.

Researchers found that GLP-1 medications such as Ozempic and Mounjaro were associated with a 17% lower cancer risk compared to non-users. Cancer incidence was lower for 12 of 13 obesity-related cancers, plus lung cancer. In particular, taking GLP-1 medications was associated with a reduced risk of endometrial and ovarian cancers and meningioma, but researchers noted an increased risk of kidney cancer.

UF co-authors include Thomas George, M.D., deputy director of the UF Health Cancer Center; Yi Guo, PhD, FAMIA, and Yongqiu Li, M.S., from the UF Department of Health Outcomes & Biomedical Informatics; Ramon Sun, Ph.D., an investigator with the UF Health Cancer Center and McKnight Brain Institute of the University of Florida; Serena Jingchuan Guo, M.D., Ph.D., Ying Lu, B.A., and Yao An Lee, M.S., from the University of Florida College of Pharmacy; and William Troy Donahoo, M.D., from the University of Florida College of Medicine.

M	T	W	T	F	S	S
				1	2	3
4	5	6	7	8	9	10
11	12	13	14	15	16	17
18	19	20	21	22	23	24
25	26	27	28	29	30	31

Science

OncoDaily

Science

GLP-1 Receptor Agonists and Cancer Risk in Adults With Obesity – UF Health Cancer Center